Through empowering and educating patients, funding cutting-edge research, building strategic collaborations and raising public awareness, our goal is to transform lung cancer into a chronically managed disease within 10 years and ultimately to find a cure.

Latest News
FDA Approves KEYTRUDA as First-Line Combination Therapy, Irrespective of PD-L1 ExpressionFDA Approves KEYTRUDA as First-Line Combination Therapy, Irrespective of PD-L1 Expression // Congratulations, Merck, for the approval of KEYTRUDA® in first-line combo therapy irrespective of PD-1 expression. The improved responses seen with KEYTRUDA® plus… Read More READ MORE
New Clinical Trial for Non-squamous Non-small Cell Lung CancerNew Clinical Trial for Non-squamous Non-small Cell Lung Cancer // A new study led by researchers at the Indiana University Melvin and Bren Simon Cancer Center may help answer questions about the role of immunotherapy in combination with chemotherapy in... Read More READ MORE
New Video Celebrating ALCF Founder Bonnie AddarioNew Video Celebrating ALCF Founder Bonnie Addario // Watch as patients, caregivers, staff, researchers, and doctors talk about the impact Bonnie has had on the the fight against lung cancer and give thanks for the impact she’s had... Read More READ MORE
Check Out the Latest News From ALCMICheck Out the Latest News From ALCMI // The Addario Lung Cancer Medical Institute’s (ALCMI) CASTLE study provides a unique foundational resource enabling scientists to ask and answer critical questions around the biology of lung cancer, and has... Read More READ MORE
Are you a ROS1+ patient?Are you a ROS1+ patient? // ALCF launched its Global ROS1 Initiative in 2016 to accelerate research into this understudied type of cancer. Learn more about how YOU can participate as we add the new ROS1... Read More READ MORE